

L7 ANSWER 19 OF 62 HCAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 1997:332024 HCAPLUS  
 DOCUMENT NUMBER: 126:308827  
 TITLE: Peripherally active anti-hyperalgesic opiates  
 INVENTOR(S): Yaksh, Tony L.; Farrar, John J.; Maycock, Alan L.;  
 Lewis, Michael E.; Dow, Gordon J.  
 PATENT ASSIGNEE(S): Regents of the University of California, USA; Adolor  
 Corporation; Yaksh, Tony L.; Farrar, John J.;  
 Maycock,  
 Alan L.; Lewis, Michael E.; Dow, Gordon J.  
 SOURCE: PCT Int. Appl., 317 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9709973	A2	19970320	WO 1996-US14727	19960912 <--
WO 9709973	A3	19970605		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG				
US 5849761	A	19981215	US 1995-528510	19950912
CA 2229814	AA	19970320	CA 1996-2229814	19960912 <--
AU 9670710	A1	19970401	AU 1996-70710	19960912 <--
AU 727982	B2	20010104		
EP 852494	A2	19980715	EP 1996-931567	19960912
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
BR 9610345	A	19990601	BR 1996-10345	19960912
JP 11512438	T2	19991026	JP 1996-512136	19960912
JP 2002069004	A2	20020308	JP 2001-224729	19960912
NO 9800700	A	19980512	NO 1998-700	19980219
US 6166039	A	20001226	US 1998-199873	19981124
PRIORITY APPLN. INFO.:			US 1995-528510	A 19950912
			JP 1997-512136	A3 19960912
			WO 1996-US14727	W 19960912

OTHER SOURCE(S): MARPAT 126:308827

AB Comps. and methods using the comps. for treatment of peripheral  
 hyperalgesia are provided. The comps. contain an anti-hyperalgesia  
 effective amt. of one or more comps. that directly or indirectly  
 interact


with peripheral opiate receptors, but that do not, upon topical or local  
 administration, elicit substantial central nervous system effects. The  
 anti-diarrheal compd. loperamide-HCl is preferred for use in the comps.  
 and methods.

IT 3810-35-3, Tenonitrozole

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (peripherally active anti-hyperalgesic opiates)


RN 3810-35-3 HCAPLUS

CN 2-Thiophenecarboxamide, N-(5-nitro-2-thiazolyl)- (7CI, 8CI, 9CI) (CA  
INDEX NAME)



AN 2002:314913 CAPLUS  
 DN 136:340689  
 TI Preparation of urea derivatives containing nitrogenous aromatic ring compounds as inhibitors of angiogenesis  
 IN Funahashi, Yasuhiro; Tsuruoka, Akihiko; Matsukura, Masayuki; Haneda, Toru; Fukuda, Yoshio; Kamata, Junichi; Takahashi, Keiko; Matsushima, Tomohiro; Miyazaki, Kazuki; Nomoto, Kenichi; Watanabe, Tatsuo; Obaishi, Hiroshi; Yamaguchi, Atsumi; Suzuki, Sachi; Nakamura, Katsuji; Mimura, Fusayo; Yamamoto, Yuji; Matsui, Junji; Matsui, Kenji; Yoshiba, Takako; Suzuki, Yasuyuki; Arimoto, Itaru  
 PA Eisai Co., Ltd., Japan  
 SO PCT Int. Appl., 699 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002032872	A1	20020425	WO 2001-JP9221	20011019
	WO 2002032872	C1	20020926		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2001095986	A5	20020429	AU 2001-95986	20011019
PRAI	JP 2000-320420	A	20001020		
	JP 2000-386195	A	20001220		
	JP 2001-46685	A	20010222		
	WO 2001-JP9221	W	20011019		
OS	MARPAT 136:340689				
GI					



AB N-aryl or N-heteroarylurea derivs. represented by the general formula Ag-Xg-Yg-Tg1 or salts thereof, or hydrates of both [wherein Ag = (un)substituted C6-14 aryl or 5- to 14-membered heterocyclic group; Xg = single bond, O, S, C1-6 alkylene, SO, SO2, (un)substituted NH; Yg = (un)substituted C6-14 aryl, 5- to 14-membered heterocyclic group, C1-8 alkyl, C3-8 alicyclic hydrocarbyl, C6-14 aryl-C1-6 alkyl, 5- to 14-membered heteroaryl-C1-6 alkyl, (CH2)gSO2 (g = 1-8), (CH2)faCH:CH(CH2)fb (fa, fb = 0, 1, 2, 3), etc.; and Tg1 = a group of the general formula -Eg-CO-NRg1(Zg) or Q; wherein Eg = a single bond, (un)substituted NH; Rg1 = H, (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 aliph. hydrocarbyl, etc.; Zg = C1-8 alkyl, C3-8 alicyclic hydrocarbyl, C6-14 aryl, etc.; Zg1, Zg2 = (a) a single bond, (b) C1-6 alkylene optionally having .gtoreq.1 atoms selected from O, S, and N in the middle or the terminus of the chain and optionally substituted with oxo, (c) (un)substituted C2-6 alkenyl] are prepd. These compds. are also

inhibitors of vascular endothelial growth factor receptor kinase (VEGFR2 kinase) and are useful as antitumor agents against hemangioma, pancreatic cancer, stomach cancer, colon cancer, breast cancer, prostate cancer, lung cancer, brain tumor, leukemia, or ovarian cancer, as cancer metastasis inhibitors, and for the treatment of retina neovascularization, diabetic retinopathy, atherosclerosis, or inflammatory diseases such as osteoarthritis, rheumatoid arthritis, psoriasis, or delayed hypersensitivity. Thus, to soln. of 334 mg 4-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenylamine in 4 mL DMF were added 0.066 mL pyridine and 0.102 mL Ph chlorocarbonate and stirred at room temp. for 2.5 h to give 330 mg N-[4-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenyl]-N'-cyclopropylurea which (260 mg) was hydrogenolyzed over platinum oxide in ethanol overnight to give 160 mg N-[4-[6-(4-hydroxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenyl]-N'-cyclopropylurea (I). I showed IC50 of 0.02 nM for inhibiting the vascular endothelial growth factor (VEGF)-stimulated sandwich tube formation in vascular endothelial cell.


IT 417714-24-0P 417714-55-7P 417715-20-9P  
417715-27-6P 417715-42-5P 417715-47-0P  
417715-59-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of urea derivs. contg. nitrogenous arom. ring compds. as angiogenesis inhibitors for prevention or treatment of diseases)


RN 417714-24-0 CAPLUS

CN Urea, N-[6-[(6,7-dimethoxy-4-quinolinyl)oxy]-3-pyridinyl]-N'-2-thiazolyl- (9CI) (CA INDEX NAME)




RN 417714-55-7 CAPLUS

CN Urea, N-[5-[(6-phenyl-1H-pyrrolo[2,3-d]pyrimidin-4-yl)thio]-2-thienyl]-N'-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 417715-20-9 CAPLUS


CN Urea, N-[5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl]-N'-2-thiazolyl-  
(9CI) (CA INDEX NAME)



\*\*\* FRAGMENT DIAGRAM IS INCOMPLETE \*\*\*


RN 417715-27-6 CAPLUS

CN Urea, N-[5-[(6,7-dimethoxy-4-quinolinyl)thio]-2-thienyl]-N'-2-thiazolyl-  
(9CI) (CA INDEX NAME)




RN 417715-42-5 CAPLUS

CN Urea, N-[2-[(6,7-dimethoxy-4-quinolinyl)thio]-5-thiazolyl]-N'-2-thiazolyl-  
(9CI) (CA INDEX NAME)




RN 417715-47-0 CAPLUS

CN 6-Quinolinecarboxamide, 7-methoxy-4-[[5-[[2-thiazolylamino]carbonyl]amino]-2-thienyl]thio]- (9CI) (CA INDEX NAME)



RN 417715-59-4 CAPLUS

CN Urea, N-[5-[[6-cyano-7-(2-methoxyethoxy)-4-quinolinyl]thio]-2-thienyl]-N'-2-thiazolyl- (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT